Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
Public ClinicalTrials.gov record NCT03272633. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Post-Transplant Use of Irradiated Haplo-Allogeneic Cells
Study identification
- NCT ID
- NCT03272633
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Early Phase 1
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Enrollment
- 2 participants
Conditions and interventions
Conditions
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia in Remission
- Hematopoietic Cell Transplantation Recipient
- JAK2 Gene Mutation
- Loss of Chromosome 17p
- Mantle Cell Lymphoma
- Minimal Residual Disease
- Myelodysplastic Syndrome
- Non-Hodgkin Lymphoma
- Plasma Cell Myeloma
- RAS Family Gene Mutation
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Hematologic Malignancy
- Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- TP53 Gene Mutation
- Therapy-Related Acute Myeloid Leukemia
- Therapy-Related Myelodysplastic Syndrome
Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation Procedure
- Irradiated Allogeneic Cells Biological
Procedure · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 25, 2020
- Primary completion
- Jun 29, 2022
- Completion
- Sep 21, 2022
- Last update posted
- Jun 25, 2023
2020 – 2022
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03272633, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 25, 2023 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03272633 live on ClinicalTrials.gov.